NCT06999252

Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients

The Combination of Rimegepant and PD-1 Inhibitor in the Treatment of Liver Metastasis Colorectal Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about efficacy of Rimegepant in combination with PD-1 in patients with liver metastasis colorectal cancer. The main question is to explore the survival time, safety and tolerability of the treatment. At the same time, the correlation between biomarkers (including PD-L1 expression, tumor mutation load, lymphocyte subpopulation, cytokines, TCR, intestinal microbes, and others) and the efficacy and drug resistance mechanism will be analyzed, so as to provide reference for the subsequent guidance of the screening of benefit groups.

Conditions

• Colon Cancer

Interventions

Type	Name	Description
DRUG	Rimegepant	Take 75 mg every other day
DRUG	PD-1	200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.

Timeline

• Start date: 2025-07-01
• Primary completion: 2028-12-01
• Completion: 2029-06-01
• First posted: 2025-05-31
• Last updated: 2025-05-31

Locations

1 site across 1 country: China